Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Key Inclusion Criteria: * Willing and able to provide written informed consent * HCV RNA ≥ 10\^4 IU/mL at screening * HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting antiviral agent, or HCV treatment-experienced (HCV genotype 1, 2, 3, or 6 only) with medical records that include sufficient detail of prior treatment with IFN to allow for categorization of prior response as either IFN Intolerant, non-responder, or experiences viral breakthrough or relapse * HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy Key Exclusion Criteria: * Current or prior history of any clinically-significant illness (other than HCV) * Pregnant or nursing female or male with pregnant female partner * Chronic liver disease of a non-HCV etiology * Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Note: Other protocol defined Inclusion/Exclusion criteria may apply.